目的 探討百樂眠膠囊聯(lián)合富馬酸喹硫平片治療輕中度抑郁癥的臨床療效。方法 選取2019年6月—2020年6月天津港口醫(yī)院收治的100例輕中度抑郁癥患者，按照隨機(jī)數(shù)字表法將全部患者分為對(duì)照組和治療組，每組各50例。對(duì)照組口服富馬酸喹硫平片，2次/d，總劑量第1天50 mg，第2天100 mg，第3天200 mg，第4天300 mg，根據(jù)患者的耐受性和臨床反應(yīng)保持劑量150～750 mg/d。治療組在對(duì)照組基礎(chǔ)上口服百樂眠膠囊，4粒/次，2次/d。兩組患者連續(xù)治療1個(gè)月。觀察兩組患者治療后的總有效率，比較漢密爾頓抑郁量表（HAMD-24）評(píng)分、抑郁自評(píng)量表（SDS）評(píng)分、世界衛(wèi)生組織生存質(zhì)量量表（WHOQOL-BREF）評(píng)分以及血清腦源性神經(jīng)營(yíng)養(yǎng)因子（BDNF）、白細(xì)胞介素-18（IL-18）、5-羥色胺（5-HT）水平。結(jié)果 治療后，治療組患者的總有效率為94.00%，對(duì)照組的總有效率為78.00%，兩組組間具有明顯差異（P<0.05）。治療后，兩組的HAMD-24評(píng)分、SDS評(píng)分均明顯降低（P<0.05）；治療后，治療組的HAMD-24評(píng)分、SDS評(píng)分比對(duì)照組低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的生理、心理、社會(huì)關(guān)系、環(huán)境評(píng)分顯著升高（P<0.05），治療后治療組生理、心理、社會(huì)關(guān)系、環(huán)境評(píng)分升高的更明顯（P<0.05）。治療后，兩組的BDNF、5-HT水平顯著升高，IL-18水平顯著降低（P<0.05）；治療組的BDNF、5-HT水平比對(duì)照組高，IL-18水平比對(duì)照組低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 百樂眠膠囊聯(lián)合富馬酸喹硫平片治療抑郁癥的療效確切，可減輕臨床癥狀，改善生活質(zhì)量，調(diào)節(jié)BDNF、5-HT、IL-18水平的分泌，且安全性良好。

Objective To investigate the clinical efficacy of Bailemian Capsules combined with Quetiapine Fumarate Tablets in treatment of mild to moderate depression. Methods Patients (100 cases) with mild to moderate depression in Tianjin Port Hospital from June 2019 to June 2020 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Quetiapine Fumarate Tablets, twice daily, the total dose was 50 mg on the first day, 100 mg on the second day, 200 mg on the third day, and 300 mg on the fourth day according to the patient's tolerance and clinical response, and the dose was maintained at 150-750 mg/d. Patients in the treatment group were po administered with Bailemian Capsules on the basis of the control group, 4 grains/time, twice daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the HAMD-24 score, the SDS score, the WHOQOL-BREF score, and the levels of BDNF, IL-18, and 5-HT in two groups were compared. Results After treatment, the total effective rate was 94.00% in the treatment group and 78.00% in the control group, and there was significant difference between the two groups (P < 0.05). After treatment, the HAMD-24 score and SDS score of two groups were significantly reduced (P < 0.05). After treatment, the HAMD-24 score and SDS score of the treatment group were lower than those of the control group (P <0.05). After treatment, physical scores, psychological scores, social relationship scores, and environmental scores in two groups were significantly increased (P < 0.05). After treatment, physical scores, psychological scores, social relationship scores, and environmental scores in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of BDNF and 5-HT in two groups were significantly increased, but the level of IL-18 in two groups were significantly decreased (P < 0.05). The levels of BDNF and 5-HT in the treatment group were higher than those in the control group, while the IL-18 level in the treatment group was lower than that in the control group (P < 0.05). Conclusion Bailemian Capsules combined with Quetiapine Fumarate Tablets is effective in treatment of mild to moderate depression, and can relieve the clinical symptoms, regulate the secretion of BDNF, 5-HT, and IL-18, improve the quality of life, with good safety.

R971

北京市保健科研課題項(xiàng)目（京13-01號(hào)）